Characteristics of Patients With Either ALCL or Non-ALCL
| Characteristic . | Anaplastic . | Nonanaplastic . | P . |
|---|---|---|---|
| No. | 146 | 1,695 | |
| n (%) | n (%) | ||
| Sex | |||
| M | 94 (64) | 918 (54) | |
| F | 52 (36) | 777 (46) | .018 |
| Age (yr) | |||
| ≤60 | 107 (73) | 988 (58) | |
| >60 | 39 (27) | 707 (42) | <.0001 |
| Performance status* | |||
| 0-1 | 103 (72) | 1,221 (74) | |
| >1 | 40 (28) | 420 (26) | .5 |
| B symptoms* | |||
| Absent | 67 (47) | 939 (58) | |
| Present | 77 (53) | 673 (42) | .006 |
| Mediastinal involvement | 55 (38) | 539 (32) | .2 |
| Extranodal sites | |||
| Bone marrow | 21 (15) | 268 (17) | .5 |
| Liver | 17 (12) | 188 (11) | .8 |
| Spleen | 26 (18) | 333 (20) | .6 |
| Central nervous system | 11 (8) | 129 (8) | 1 |
| Skin | 22 (15) | 93 (5) | <.0001 |
| Lung | 23 (16) | 210 (12) | .05 |
| Gut | 10 (7) | 277 (16) | .002 |
| Bone | 12 (8) | 138 (8) | 1 |
| Waldeyer's ring | 11 (8) | 187 (11) | .2 |
| No. of extranodal sites | |||
| 0-1 site | 112 (77) | 1,290 (76) | |
| >1 sites | 34 (23) | 405 (24) | .9 |
| Ann Arbor stage | |||
| I-II | 59 (40) | 683 (41) | |
| III-IV | 87 (60) | 969 (59) | .8 |
| LDH level* | |||
| ≤1 × normal | 69 (50) | 659 (43) | |
| >1 × normal | 68 (50) | 877 (57) | .09 |
| Albumin level* | |||
| ≤30 g/L | 34 (24) | 271 (17) | |
| >30 g/L | 106 (76) | 1,294 (83) | .04 |
| International prognostic index31* | |||
| Low | 63 (45) | 564 (36) | |
| Low-intermediate | 28 (20) | 405 (26) | |
| High-intermediate | 23 (17) | 349 (22) | |
| High | 25 (18) | 253 (16) | .08 |
| Treatment received | |||
| ACVBP | 69 (47) | 714 (42) | |
| m-BACOD | 22 (15) | 187 (11) | |
| NCVBP | 22 (15) | 251 (15) | |
| VIMMM | 18 (12) | 241 (14) | |
| CVP/CTVP | 15 (10) | 302 (18) | .2 |
| Characteristic . | Anaplastic . | Nonanaplastic . | P . |
|---|---|---|---|
| No. | 146 | 1,695 | |
| n (%) | n (%) | ||
| Sex | |||
| M | 94 (64) | 918 (54) | |
| F | 52 (36) | 777 (46) | .018 |
| Age (yr) | |||
| ≤60 | 107 (73) | 988 (58) | |
| >60 | 39 (27) | 707 (42) | <.0001 |
| Performance status* | |||
| 0-1 | 103 (72) | 1,221 (74) | |
| >1 | 40 (28) | 420 (26) | .5 |
| B symptoms* | |||
| Absent | 67 (47) | 939 (58) | |
| Present | 77 (53) | 673 (42) | .006 |
| Mediastinal involvement | 55 (38) | 539 (32) | .2 |
| Extranodal sites | |||
| Bone marrow | 21 (15) | 268 (17) | .5 |
| Liver | 17 (12) | 188 (11) | .8 |
| Spleen | 26 (18) | 333 (20) | .6 |
| Central nervous system | 11 (8) | 129 (8) | 1 |
| Skin | 22 (15) | 93 (5) | <.0001 |
| Lung | 23 (16) | 210 (12) | .05 |
| Gut | 10 (7) | 277 (16) | .002 |
| Bone | 12 (8) | 138 (8) | 1 |
| Waldeyer's ring | 11 (8) | 187 (11) | .2 |
| No. of extranodal sites | |||
| 0-1 site | 112 (77) | 1,290 (76) | |
| >1 sites | 34 (23) | 405 (24) | .9 |
| Ann Arbor stage | |||
| I-II | 59 (40) | 683 (41) | |
| III-IV | 87 (60) | 969 (59) | .8 |
| LDH level* | |||
| ≤1 × normal | 69 (50) | 659 (43) | |
| >1 × normal | 68 (50) | 877 (57) | .09 |
| Albumin level* | |||
| ≤30 g/L | 34 (24) | 271 (17) | |
| >30 g/L | 106 (76) | 1,294 (83) | .04 |
| International prognostic index31* | |||
| Low | 63 (45) | 564 (36) | |
| Low-intermediate | 28 (20) | 405 (26) | |
| High-intermediate | 23 (17) | 349 (22) | |
| High | 25 (18) | 253 (16) | .08 |
| Treatment received | |||
| ACVBP | 69 (47) | 714 (42) | |
| m-BACOD | 22 (15) | 187 (11) | |
| NCVBP | 22 (15) | 251 (15) | |
| VIMMM | 18 (12) | 241 (14) | |
| CVP/CTVP | 15 (10) | 302 (18) | .2 |
Data were unavailable for some patients.